
Can any of the new obesity medications in development stand out from the pack? Which company just broke records with its IPO? And will the Food and Drug Administration allow greater access to experimental peptides? We discuss all that and more on this week’s episode of “The Readout LOUD,” STAT’s biotech podcast.[2:37 PM]Undark’s Sara Talpos joins the podcast to discuss her reporting on the peptide BPC-157, and how its jumped from a Croatian lab to bodybuilding forums on Reddit to the FDA. (STAT co-published Talpos articles; the second piece was was supported by the Pulitzer Center). We also discuss the latest news in the life sciences, including obesity data from the American Diabetes Association meeting and a record-breaking IPO.
Podzilla Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.

404: What RevMed's pancreatic cancer drug meant for one patient

403: Biotech exec Jeremy Levin on the industry's strategic turning point

402: Guarding biotech from China and big bets in longevity

401: Makary’s departure and Cassidy’s tenuous Senate seat
Free AI-powered recaps of The Readout Loud and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.